Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-β signaling pathway
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE To test whether platelets could increase invasion potential and initiate EMT in ovarian cancer cells via a TGF-β signaling pathway. METHODS Blood samples were collected in 69 patients with ovarian cancer, 16 patients with benign ovarian tumor and 64 healthy donors. SK-OV-3 and OVCAR-3 ovarian cancer cells were treated with platelets. Transwell assays were used to analyze the invasive capacity, and EMT was assessed by microarray analysis, quantitative real-time PCR (qPCR) and Western blotting. Activation of TGF-β pathway was examined by ELISA and Western blotting. TGF-β type I receptor (TβR I) inhibitor A83-01 was used to confirm the role of TGF-β pathway in vitro and in vivo. RESULTS Clinical data showed ovarian cancer patients with elevated platelet counts had a higher incidence of advanced stages. Treatment with platelets increased the invasive properties of both cell lines. Mesenchymal markers (snail family transcriptional repressor-1, vimentin, neural cadherin, fibronectin-1 and matrix metalloproteinase-2) were up-regulated in platelet-treated cells, while the epithelial marker (epithelial cadherin) was down-regulated. Higher TGF-β level was observed in patients with elevated platelet counts when compared to the subjects. Higher levels of TGF-β were also found in culture medium treated with platelets, and cells treated with platelets also showed increased phosphorylation of Smad2. TβR I inhibitor A83-01 reversed the EMT-like alterations and inhibited platelet-induced invasion in vitro and in vivo. CONCLUSION Platelet increased invasion potential and induced EMT in ovarian cancer cells in a TGF-β dependent pathway. Platelet-derived TGF-β may be useful as a new target treatment for ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Labelle, M., Begum, S., & Hynes, R. O. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.009 · Cited by 1,833
Signaling mechanisms of the epithelial-mesenchymal transition
Gonzalez, D. M., & Medici, D. (2014) · Science Signaling · doi:10.1126/scisignal.2005189 · Cited by 1,721
Paraneoplastic thrombocytosis in ovarian cancer
Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., Rupaimoole, R., Armaiz-Pena, G. N., Pecot, C. V., Coward, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110352 · Cited by 812
Cited by
Circulating tumor cells: biology and clinical significance
Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., Zhu, F., Zhou, D., Zheng, S., Chen, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00817-8 · Cited by 993
Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020) · Genes · doi:10.3390/genes11111342 · Cited by 168
“In fact, inhibition of TGF-β signaling pathway using chemical inhibitors blocks EMT in multiple types of cancers [49,50].”
BackgroundSaha, B., Mathur, T., Tronolone, J. J., Chokshi, M., Lokhande, G. K., Selahi, A., Gaharwar, A. K., Afshar-Kharghan, V., Sood, A. K., Bao, G., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg5283 · Cited by 90
Platelets in aging and cancer—“double-edged sword”
Faria, A. V. S., Andrade, S. S., Peppelenbosch, M. P., Ferreira-Halder, C. V., & Fuhler, G. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09926-2 · Cited by 38
Generation of a Three-Dimensional In Vitro Ovarian Cancer Co-culture Model for Drug Screening Assays
Tofani, L. B., Sousa, L. O., Luiz, M. T., Abriata, J. P., Marchetti, J. M., Leopoldino, A. M., & Swiech, K. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.04.003 · Cited by 14
Metadata
- Authors
- Guo, Y., Cui, W., Pei, Y., & Xu, D.
- Venue
- Gynecologic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 153
- Issue
- 3
- Pages
- 639-650
- ISSN
- 0090-8258 (ISSN-L)
- OpenAlex
- W2931478334
- Cited by
- 112
- References
- 4
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.